Thromboplastin Calibration

Summary

Standardization of the thromboplastin most commonly used for anticoagulant control in The Netherlands has been achieved by the Dutch Reference Laboratory for Anticoagulant Control. The system established for control indicates the performance characteristics of each batch of thromboplastin in patients relative to a national calibration batch. Calibration constants were assessed according to an ICTH/ICSH proposal and with a reproducibility of approximately 2% (CV). With the use of a given calibration constant of the International Reference Preparation of Thromboplastin (1.0) and after assessment of the calibration constant of the National Reference Preparation in international terms (0.93), the accuracy of calibration with the various modifications of the calibration procedure is of the order of magnitude of 3% (CV). On the basis of the calibration protocol, physicians will be provided with correlation tables containing, for their convenience, prothrombin (thromboplastin) times in terms of the reference thromboplastin (uniform, i. e., batch-independent, prothrombin times), conventional prothrombin activity (percentages), and in due course with International Calibrated Ratios.* With this approach current practice in the prescription of oral anticoagulants will be maintained. Opportunity is given, however, to aim at internationally proposed therapeutically optimal target values.

• References

• 1 Averdunk R, Borner K. 1974; Standardisierung des Quick-Testes Referenz-Thromboplastin oder Referenz-Plasmen. Blut 28: 445
• 2 Bailey EL, Harper TA, Pinkerton PH. 1971; The “therapeutic range” of the one-stage prothrombin time in the control of anticoagulant therapy. The effect of different thromboplastin preparations Canadian Medical Association Journal 105: 1041
• 3 Bangham DR, Biggs R, Brozovic M, Denson KW E. 1973; Calibration of five different thromboplastins, using fresh and freeze-dried plasma. Thrombosis et Diathesis Haemorrhagica 29: 228
• 4 Bangham DR, Loeliger EA. 1977 Stability of the WHO international reference preparation (former ICTH reference thromboplastin 67/40). Thrombosis and Haemostasis, to be published.
• 5 Biggs R, Denson KW E. 1967; Standardization of the one-stage prothrombin time for the control of anticoagulant therapy. British Medical Journal 1: 84
• 6 Biggs R, Bangham DR. 1971; Standardization of the one-stage prothrombin time test for the control of anticoagulant therapy. Availability and use of thromboplastin reference preparations British Medical Journal 3: 470
• 7 Boekhout-Mussert MJ, Kolk-Schaap PJ, Van Der Hermans J, Loeliger EA. 1978 Comparative study of the clinical validity of the three types of thromboplastin (human, ox, and rabbit). To be published
• 8 Bradlow BA, Saunders C, Whitbread P, Lurie A, Penfold GK, Metz J. 1974; Standardisation of the laboratory control of anticoagulant therapy. South African Medical Journal 48: 1857
• 9 Brozovic M, Gurd LJ, Robertson I, Bangham DR. 1971; Stability of prothrombin and factor VII in freeze-dried plasma. Journal of Clinical Pathology 24: 690
• 10 Brozovic M, Howarth DJ, Halem-Visser LP, Van. Loeliger EA. 1973; Stability of freeze-dried plasma prepared from patients on oral anticoagulants. Journal of Clinical Pathology 26: 857
• 11 Denson KW E. 1971; International and national standardization of control of anticoagulant therapy in patients receiving coumarin and indanedione drugs using calibrated thromboplastin preparations. Journal of Clinical Pathology 24: 460
• 12 Duk-Wierda CA, Van Hermans J, Loeliger EA, Roos J. 1977; Interlaboratory oral anticoagulant quality assessment by the Netherlands Federation of Thrombosis Services. Thrombosis and Haemostasis 37: 509
• 13 Grimmer Ø. 1977 Personal communication.
• 14 Ingram GI C, Hills M. 1976; Reference method for the one-stage prothrombin time test on human blood. Thrombosis and Haemostasis 36: 231
• 15 Ingram GI C, Hills M. 1978 Second draft report of the ICSH/ICTH Expert Panel on Oral Anticoagulant Control, presented at the occasion of the 22nd Annual Meeting of the International Committee on Thrombosis and Haemostasis, Kyoto 1976. To be published
• 16 Kahan J, Noren I. 1975; Use of a lyophilized reference plasma to compare coagulation test procedures. Thrombosis et Diathesis Haemorrhagica 34: 426
• 17 Loeliger EA. 1972; Progress in the control of oral anticoagulation. Thrombosis et Diathesis Haemorrhagica 28: 109
• 18 Loeliger EA. 1974; Performance characteristics of reference thromboplastins. American Journal of Clinical Pathology 62: 574
• 19 Loeliger EA, Halem-Visser LP. 1975; A simplified thromboplastin calibration procedure for standardization of anticoagulant control. Thrombosis et Diathesis Haemorrhagica 33: 172
• 20 Loeliger EA, Duk-Wierda CA, Van. Roos J. 1977. Quality control and standardization of the prothrombin time. Second International Symposion on Quality Control Tokyo: 1976
• 21 Loeliger EA, Duk-Wierda CA, Van. Roos J. 1977; Qualitàtskontrolle und Standardisierung der Prothrombinzeitbestimmung zur Kontrolle oraler Antikoagulation. Blut 34: 147
• 22 Loeliger EA. 1977; Stability studies on lyophilized reference thromboplastins for standardization of prothrombin times. Lancet 2: 1279
• 23 Miale JB, Kent JW. 1972; Standardization of the therapeutic range for oral anticoagulants based on standard reference plasmas. American Journal of Clinical Pathology 57: 80
• 24 Owren PA. 1959; Thrombotest. A new method for controlling anticoagulant therapy Lancet 2: 3
• 25 Patterson BB, Puls JL. 1976; Standardization of prothrombin and activated partial thromboplastin time reagents and controls. American Journal of Clinical Pathology 65: 213
• 26 Poller L. 1967; A national standard for anticoagulant therapy. Lancet 1: 491
• 27 Poller L. 1975; The British system for anticoagulant control. Thrombosis et Diathesis Haemorrhagica 33: 157
• 28 Thomson JM, Chart IS. 1970; The system for laboratory control of oral anticoagulant therapy using the British Comparative Thromboplastin. Journal of Medical Laboratory Technology 27: 207
• 29 Zucker S, Cathey MH, Sox PJ, Hall EC. 1969; Standardization of laboratory tests for controlling anticoagulant therapy. American Journal of Clinical Pathology 53: 348